Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Bleakley Financial Group LLC

Bleakley Financial Group LLC raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,237 shares of the medical equipment provider’s stock after purchasing an additional 129 shares during the period. Bleakley Financial Group LLC’s holdings in Lantheus were worth $200,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the last quarter. CWM LLC lifted its position in Lantheus by 63.0% during the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 290 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Lantheus by 57.1% during the third quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 460 shares during the last quarter. Procyon Advisors LLC lifted its holdings in shares of Lantheus by 16.0% in the 3rd quarter. Procyon Advisors LLC now owns 3,252 shares of the medical equipment provider’s stock worth $357,000 after acquiring an additional 449 shares during the last quarter. Finally, Creative Planning boosted its holdings in Lantheus by 5.4% during the 3rd quarter. Creative Planning now owns 24,988 shares of the medical equipment provider’s stock valued at $2,742,000 after acquiring an additional 1,274 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $82.10 on Thursday. Lantheus Holdings, Inc. has a fifty-two week low of $54.69 and a fifty-two week high of $126.89. The company has a market capitalization of $5.71 billion, a price-to-earnings ratio of 13.66 and a beta of 0.44. The stock has a fifty day moving average of $91.76 and a two-hundred day moving average of $98.13.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LNTH shares. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial restated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.